Alzheimer's drugs benefit 'trivial'

The extensive review analyzed data from 17 clinical trials of anti-amyloid drugs, including the licensed medications lecanemab and donanemab.

Researchers found that while the drugs successfully remove amyloid from the brain, they do not result in a meaningful improvement in cognitive function.

Some experts described the review as a 'silly paper' that should not have been published, while others hailed it as a necessary reality check for the medical industry.

The controversy highlights the ongoing debate over the effectiveness and high cost of new dementia treatments.